Influenza vaccine - BiondVax

Drug Profile

Influenza vaccine - BiondVax

Alternative Names: BVX-M001; M 001; Multimeric Multi-Epitope Polypeptide Influenza Vaccine; Multimeric-001; Multimeric-001 Universal Flu Vaccine - BiondVax; Universal Flu Vaccine - BiondVax

Latest Information Update: 12 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Weizmann Institute of Science
  • Developer BiondVax Pharmaceuticals; National Institutes of Health
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Influenza virus infections

Most Recent Events

  • 27 Mar 2018 National Institute of Allergy and Infectious Diseases initiates enrolment in a phase II trial for Influenza virus infections (Prevention) in USA (NCT03058692)
  • 02 Jan 2018 BiondVax Pharmaceuticals has patent protection for influenza vaccine (M 001) in India
  • 05 Dec 2017 BiondVax plans a phase III trial for Influenza virus infections (In adults, In the elderly) in Europe, in 2018 (NCT03450915) (CTP#260505)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top